Method for quantitative assessment of tumor volume response to neoadjuvant chemotherapy using MRI

被引：0

作者：

Partridge, S ^{[1
]}

Esserman, L ^{[1
]}

Kaplan, E ^{[1
]}

Heumann, E ^{[1
]}

Weidner, N ^{[1
]}

Hylton, N ^{[1
]}

机构：

[1] Univ Calif Berkeley, Joint Grad Grp Bioengn, Berkeley, CA 94720 USA

来源：

PROCEEDINGS OF THE 22ND ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-4 | 2000年 / 22卷

关键词：

magnetic resonance imaging; breast tumors; neoadjuvant chemotherapy; treatment response; tumor volume; image segmentation;

D O I：

暂无

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Neoadjurant chemotherapy is an effective treatment for locally advanced breast cancer (LABC). Response of a tumor to preoperative chemotherapy is a valuable predictor of a patient's overall survival. We hypothesize that magnetic resonance imaging (MRI) may be more predictive of patient outome than clinical exam by providing quantitative assessments of extent of cancer in the breast and the change In response to neoadjuvant treatment. The purpose of this study was to investigate whether MRI can accurately quantify changes in tumor size in response to treatment. MRI size measurements were compared to clinical response assessments and post-surgical pathology data in a group of women with LABC. The MR techniques accurately characterized size of residual disease in the breast and demonstrated predictive value for treatment outcome.

引用

页码：1645 / 1647

页数：3

共 7 条

[1] Utility of magnetic resonance imaging in the management of breast cancer: Evidence for improved preoperative staging [J].

Esserman, L ;

Hylton, N ;

Yassa, L ;

Barclay, J ;

Frankel, S ;

Sickles, E .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :110-119

[2]

Harms S E, 1996, Curr Probl Diagn Radiol, V25, P193

[3]

HORTOBAGYI GN, 1988, CANCER, V62, P2507, DOI 10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO

[4]

2-D

[5]

Hylton NM, 1998, RADIOLOGY, V209P, P468

[6] Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [J].

Kuerer, HM ;

Newman, LA ;

Smith, TL ;

Ames, FC ;

Hunt, KK ;

Dhingra, K ;

Theriault, RL ;

Singh, G ;

Binkley, SM ;

Sneige, N ;

Buchholz, TA ;

Ross, MI ;

McNeese, MD ;

Buzdar, AU ;

Hortobagyi, GN ;

Singletary, SE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :460-469

[7]

Partridge SC, 1999, ST HEAL T, V62, P259

← 1 →